Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Los Angeles Times - October 22, 2004
Denise Gellene, Times Staff Writer
The Foster City, Calif.-based company said net income rose 55% in the quarter, driven by strong sales of its mainstay AIDS pill Viread.
The results were marred by news that Gilead had discontinued work on two potential AIDS drugs because of disappointing test results - a setback for the company's development program. One was a follow-on to Viread, one of the nation's top-selling AIDS medications.
Net income was $113.2 million, or 25 cents a share, compared with $73.1 million, or 17 cents, in the year-earlier quarter. Wall Street had expected profit of 21 cents, according to analysts surveyed by Thomson First Call.
Revenue rose to $326.2 million compared from $200.4 million.
For all of 2004, the company now expects sales of its AIDS drugs to range from $870 million to $890 million, up from a range of $850 million to $870 million. Gilead said sales of its antifungal drug Ambisome would be $195 million to $205 million.
Greg Wade of Pacific Growth Equities said Gilead's results in general were strong. He said that Gilead would probably license drugs in development at other companies to replace the potential sales of the two drugs they canceled.
Gilead announced its results after the market closed. In regular Nasdaq trading, its shares fell $1.13 to $36.68. They dipped to $33.17 in after-hours trading.
041022
LT041021
Copyright © 2004 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .